Nivolumab before and after allogeneic hematopoietic cell transplantation

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD

George P. Canellos, James R. Anderson, Kathleen J. Propert et al. · New England Journal of Medicine · 1992 · 1.2K citations · Full text

Medicine, Oncology, Radiation Oncology +14

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

Norbert Schmitz, Beate Pfistner, M. Sextro et al. · The Lancet · 2002 · 1.1K citations

Medicine, Clinical Sciences, Oncology +13

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes, Armando Santoro, Margaret A. Shipp et al. · The Lancet Oncology · 2016 · 924 citations · Full text

Medicine, Hematology, Oncology +16